News
ImmunOs Therapeutics Presents Details of Novel Bispecific Anti-Tumor Molecules at ESMO Immuno-Oncology Congress 2023
— HLA/SIRPa bispecifics targeting LILRB1/2 plus CD47 checkpoint receptor
— Designed to target myeloid, NK and T cells and to be precisely directed to tumor sites
— Potent in vitro anti-tumor efficacy demonstrated
ImmunOs Therapeutics AG, a biopharmaceutical company pioneering HLA-based therapeutics to create transformational medicines for cancer and inflammation, announced details of its novel multi-functional anti-cancer modality at ESMO Immuno-Oncology Congress 2023 in Geneva (Switzerland) on December 7, 2023.
Thermosome Appoints Dr. Frank Hermann, MD, as Chief Medical Officer and Adds Prof. Alessandro Gronchi, MD, to Clinical Advisory Board
– Two renowned oncology experts to support the development of Thermosome’s clinical candidate THE001
Thermosome, a drug development company specializing in targeted tumor therapies, today announced the appointment of Dr. Frank Hermann, MD, as Chief Medical Officer (CMO) and the expansion of its Clinical Advisory Board with the addition of Prof. Alessandro Gronchi, MD.
EBViously Presents Novel In-Vitro Data Demonstrating Potent Infection Prevention of its Vaccine Candidate EBV-001
— Presentation at the World Vaccine Congress West Coast2023
— EBV-001 is designed for the prevention of Epstein-Barr Virus (EBV)-induced diseases via high titers of potent, neutralizing antibodies
— Novel in-vitro data support preclinical proof-of-concept data
EBViously, a start-up developing novel vaccines based on next-generation virus-like particles, has presented new in vitro data of its EBV-vaccine candidate EBV-001 at the World Vaccine Congress West Coast 2023 (Nov. 27-30, 2023) in Santa Clara, CA (USA). The presentation by EBViously’s designated COO Sebastian Goy was held on Thursday, November 30, 2023. Read more…
Ebenbuild to Receive Public Funding Under UBIC Consortium for Digital Lung Twin Project
— Funding up to Euro 1.8 million awarded by German Federal Ministry of Education and Research BMBF
Ebenbuild, a company developing personalized, AI-driven virtual lungs to support clinical decisions and digital clinical trials, today announced its participation in the research project Personalized Lung Twins for the Treatment of Acute Respiratory Distress Syndrome (UBIC) in collaboration with the University Hospital Schleswig-Holstein, Augsburg University Hospital, University Hospital Carl Gustav Carus Dresden, University Hospital RWTH Aachen and University Medical Center Mannheim.